Protagenic Therapeutics, Inc.\new Debt Securities, Available-for-sale, Unrealized Loss
Protagenic Therapeutics, Inc.\new (PTIX) reported Debt Securities, Available-for-sale, Unrealized Loss of $194.59 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2022-08-11
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, unrealized loss for the quarter ending 2022-06-30 was $43.42K.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, unrealized loss for the quarter ending 2022-03-31 was $151.17K.
- Protagenic Therapeutics, Inc.\new debt securities, available-for-sale, unrealized loss for fiscal 2021 was $77.03K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|
| 2022-06-30 | $43.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $194.59K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $151.17K 10-Q · filed 2022-05-13 | ||
| 2021-12-31 | $77.03K 10-K · filed 2022-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |